Windrose Consulting Group collaborate with Cambridge University on a Executive education course on commercialisation strategy

Windrose Consulting Group are pleased to continue the New Year with two new Consultants joining our growing team. Muna Ali and Stacey McDonald

Windrose Consulting Group are pleased bring in the New Year with two new Analysts on our team and a promotion within the team.

Emerging Markets are not only influential in their own regions but represent a significant proportion of the world’s population and trade. They also represent a growing share of global healthcare spending. As such they offer an attractive growth prospect for the pharmaceutical industry.

December 1st is World AIDS Day and is an opportunity to reflect on pharmacological innovations that has turned a once fatal disease into a treatable condition. Infection rates have slowed in recent years due to increase in testing availability, as well as development of antiretroviral therapy and, more recently, pre-exposure prophylaxis (PrEP)

We are pleased to launch the first edition of our Windrose Consulting Group: Global News Roundup for Q1-Q3 2021.

In June, Windrose’s Elizaveta Tchebaniouk provided an analysis of Aduhelm’s approval in Alzheimer’s Disease (AD) and the dynamic environment surrounding Biogen’s launch in the US. High unmet need, uncertain evidence, modest clinical benefit, and affordability concerns continue to make for a highly complex commercial launch.

Windrose Consulting Group are pleased to welcome three new Analysts to our team.

Our client wanted to understand the non-muscle invasive bladder cancer (NMIBC) disease landscape, specifically for high-risk patients unresponsive to current non-surgical standard of care, for Germany, France, and Canada.

Windrose Consulting Group are pleased to announce the September promotions for our team.

Today on World Heart Day, Windrose would like to recognize all of the innovators, healthcare providers, and family caregivers who are striving to make the world a better place for those with cardiovascular diseases (CVD).

At Windrose, we have been celebrating over a year since having acquired Parioforma, a leader in value, access and price assessments in non-traditional markets. The acquisition has strengthened Windrose’s expertise in emerging markets, which has been a significant driver of growth in recent years.

Potential ripple effects for gene therapy access

Bluebird bio, one of the world’s earliest innovators in the gene therapy space, recently announced that they will move away from launching and operating in Europe as a company, driven primarily by misalignment around the value and prices of their rare disease portfolio.

Established in 1992, the Authorization for Temporary Use program in France (ATU) is among one of the oldest and most open early access programs in Europe.[1] It allows patients with rare or serious diseases access to drugs which are currently unauthorized in that indication. Although a complex process, it appeals to manufacturers, with recent funding for ATUs growing to over €1 billion a year.[2]

At Windrose, we are celebrating a year since having acquired Parioforma, a leader in value, access and price assessments in non-traditional markets. The acquisition has strengthened Windrose’s expertise in emerging markets, which has been a significant driver of growth in recent years.

In April 2019, Japan introduced its first formal health technology assessment (HTA), driven by a cost-effectiveness analysis (CEA). The CEA was introduced to adjust the price of already reimbursed products, with the overarching aim of reducing expenditure and increasing efficiency within the healthcare system. The Ministry of Health, Labour and Welfare (MHLW) recently published the first price adjustments for several listed agents, including a 4.7% reduction for Novartis’ Kymriah, and a 0.5% reduction for GlaxoSmithKline’s Trelegy.[1-4] Here we look at what the new CEA entails, how it impacts already reimbursed products, and what the road to access may look like for new drugs in the future.

We are excited to announce the promotion of Kate Hogan to Senior Consultant at Windrose Consulting Group.

Kate has shown great leadership skills, as well as impressive management of large and very high-profile projects.

We are thrilled to see Kate’s progression, which has been instrumental in our continued growth.

We are pleased to announce the opening of our new office in Lucerne, Switzerland.

On June 7th, the FDA granted accelerated approval for Biogen’s amyloid beta-directed anti-body Aduhelm (aducanumab), the first potentially disease-modifying treatment and first approval for Alzheimer’s disease (AD) in nearly two decades.

Our team at Windrose have been reflecting upon the importance of donating blood; we understand that regular blood donations are needed all over the world, to ensure individuals and communities have access to safe and quality-assured blood and blood products.